Analyst Price Target is $10.50
▲ +333.88% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aptinyx in the last 3 months. The average price target is $10.50, with a high forecast of $12.00 and a low forecast of $8.00. The average price target represents a 333.88% upside from the last price of $2.42.
Current Consensus is
The current consensus among 7 polled investment analysts is to buy stock in Aptinyx. This Buy consensus rating has held steady for over two years.
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.